Science & Technology
Clinical evaluation of BMS-984923 metabolism.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1SB1AG087748-01
Award Ceiling
$3.3M
Award Floor
$3.3M
Close Date
May 31, 2026
77 days leftTotal Funding
$3.3M
Expected Awards
1
Posted Date
Sep 20, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1SB1AG087748-01
Description
SBIR Phase Phase II award: "Clinical evaluation of BMS-984923 metabolism." awarded to ALLYX THERAPEUTICS INC in NEW HAVEN, Connecticut. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $3,347,703. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.